Search
Showing results for "aboriginal respiratory"
Findings of a research study examining the characteristics of service use by a cohort of young people born between 1994-1997 who used four government services.
Findings of a research study examining the characteristics of service use by a cohort of young people born between 1994-1997 who used four government services.
Professor Helen Milroy speaks about the importance of providing support to leading advocates after meeting with noted campaigner for a Voice to Parliament, Thomas Mayo.
Embrace 2024 Seeding Grant winners (clockwise from top left): Dr Penelope Strauss, Dr Renee Teal, Dr Melissa Licari, Dr Vincent Mancini
Project Officer Lisa Kickett will be funded by Embrace @ The Kids Research Institute Australia to complete a placement on a major parenting program research project, paving the way for her to complete her Master of Social Work degree.
Leaders of Western Australia’s youth mental health research sector from Embrace at The Kids Research Institute Australia have welcomed the state government’s $420 million boost to mental health spending in its 2023-24 budget.
Community involvement plays an integral role in guiding our research - find out how.
A The Kids Research Institute Australia study designed to gauge community awareness of respiratory syncytial virus (RSV) has found parents and parents-to-be are highly aware of the virus and are open to immunisation to tackle it.
Patients with a propensity for upper airway obstruction, including those with obstructive sleep apnea (OSA), are vulnerable in the perioperative period. OSA is an increasingly common disorder in children and, when present, is associated with an increased risk of perioperative respiratory adverse events (PRAE),1 morbidity, and mortality. Therefore, identifying at-risk patients is vital to provide tailored perioperative anesthetic management.
In 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared endemic, yet hospital admissions have persisted and risen within populations at high and moderate risk of developing severe disease, which include those of older age, and those with co-morbidities. Antiviral treatments, currently only available for high-risk individuals, play an important role in preventing severe disease and hospitalisation within this subpopulation.